Company Spotlight: How to cut hospital waiting lists and make money

The term "bed-blocking" entered the lexicon around the same time as "alcopops", "spin" and "diamond geezer".

The term "bed-blocking" entered the lexicon around the same time as "alcopops", "spin" and "diamond geezer". But the problem is not new. Patients have long tied up beds, either because they are slow to convalesce after surgery or have nowhere else (such as a nursing home) where they can go. The issue has been given new urgency by NHS target-setting. Free up beds more quickly and you improve patient throughput and reduce waiting lists.

Now a UK company has found a way of doing just that by tackling one of the prime causes of slow post-operative recovery: a fall-off in the rate at which oxygen is delivered around the body during surgery. Deltex Medical Group, which is traded on the AIM market, has invented a system for monitoring blood flow during and after surgery and allowing doctors to detect and deal with the problem through the administering of fluid and drugs.

Its monitoring system is called CardioQ. It draws data from a disposable probe that is inserted in the patient's oesophagus. A host of studies have shown CardioQ can cut recovery times by as much as two-fifths. Deltex has spent much of its time in the past 18 months persuading NHS trusts to assess the economics of CardioQ by trying it out in widescale tests. In most cases it has been funding the costs of data collection.

Now all that is changing. Medway NHS Trust in Kent adopted the system in April as a "standard of care" for all its moderate- and major-risk surgical and critical-care patients. The results of a post-procurement review showed that CardioQ cut an average of two days off the time patients stayed in hospital. In other words, the system pays for itself several times over. Deltex still has trials in another dozen or so UK hospitals, but these are expected to lead to firm orders soon.

The impact on sales - just £3m last year - will be dramatic. Deltex will make most of its money from the sale of disposable probes. It is reckoned that the deal with Medway NHS Trust will be worth upwards of £100,000 in probes - and there are 400 hospitals in the UK that could adopt the system. Deltex may not win them all, but it is worth noting that it recently appointed the former head of the NHS, Sir Duncan Nichol, as a non-executive director. That surely cannot harm its marketing effort.

At Deltex's recent shareholders' annual meeting, the chairman, Nigel Keen, said there was good feedback from the other NHS trusts auditing the results of their CardioQ trials. He suggested it was now a question of when, not if, the system was adopted on a widespread basis. There was also a good chance of a hospital in Europe or the US announcing a deal shortly. Deltex is well advanced with its marketing in parts of Europe (France especially) and the US, where CardioQ received upgraded regulatory approvals last year.

All of this has to be put in the context of a company valued on the stock market at just £16m. That figure may rise as Deltex issues more shares to fund working capital when sales build up. But this is a small company in what is potentially a big market. That market could be bigger still. Earlier this year, Deltex launched a softer probe which can be used on conscious patients - widening the range of applications for CardioQ.

Thanks to a soggy stock market, the shares have been treading water for most of this year, despite the mounting evidence that CardioQ has proved itself. I reckon they are worth picking up on a two-year view at the current 26.5p.

Now, one for risk-takers. Eurodis Electron is one of Europe's biggest distributors of electronic components - not a good market since 2001. In the past two years, Eurodis has racked up losses of £76m and only saved itself from oblivion by raising £57m in new money. Because of a shortage of cash at critical periods last year, it lost market share, which will take time to rebuild.

Despite that, all but one of its major suppliers has stuck with the company and the market has clearly turned for the better. The last set of figures had an air of throwing in the kitchen sink about them and the board has been busy picking up shares at 3p and 4p a time since they were announced.

The first priority for Eurodis will be to regain market share, so profits will lag, despite a lot of cost-cutting in the past year. But at the current 3p, the company is valued at about £28m, a touch less than net worth. Even last year sales were £225m, which gives some idea of the recovery potential. But it is probably not one for light sleepers.

Pshearlock@yahoo.co.uk

Independent Partners; Do you need financial advice on your investments, pension or insurance? Book a free consultation with an independent Financial Adviser at VouchedFor.co.uk

Finacial products from our partners
Property search
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

ES Rentals

    iJobs Job Widget
    iJobs Money & Business

    SThree: Recruitment Resourcer

    £20000 - £21000 per annum + uncapped commission: SThree: As a graduate you are...

    Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

    £25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

    Recruitment Genius: Customer Service Advisor

    £15000 - £16000 per annum: Recruitment Genius: A Customer Service Advisor is r...

    Ashdown Group: Trainee Consultant - Surrey / South West London

    £22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

    Day In a Page

    Syrian conflict is the world's first 'climate change war', say scientists, but it won't be the last one

    Climate change key in Syrian conflict

    And it will trigger more war in future
    How I outwitted the Gestapo

    How I outwitted the Gestapo

    My life as a Jew in wartime Berlin
    The nation's favourite animal revealed

    The nation's favourite animal revealed

    Women like cuddly creatures whilst men like creepy-crawlies
    Is this the way to get young people to vote?

    Getting young people to vote

    From #VOTESELFISH to Bite the Ballot
    Poldark star Heida Reed: 'I don't think a single bodice gets ripped'

    Poldark star Heida Reed

    'I don't think a single bodice gets ripped'
    The difference between America and Israel? There isn’t one

    The difference between America and Israel? There isn’t one

    Netanyahu knows he can get away with anything in America, says Robert Fisk
    Families clubbing together to build their own affordable accommodation

    Do It Yourself approach to securing a new house

    Community land trusts marking a new trend for taking the initiative away from developers
    Head of WWF UK: We didn’t send Cameron to the Arctic to see green ideas freeze

    David Nussbaum: We didn’t send Cameron to the Arctic to see green ideas freeze

    The head of WWF UK remains sanguine despite the Government’s failure to live up to its pledges on the environment
    Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

    Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

    Set in a mythologised 5th-century Britain, ‘The Buried Giant’ is a strange beast
    With money, corruption and drugs, this monk fears Buddhism in Thailand is a ‘poisoned fruit’

    Money, corruption and drugs

    The monk who fears Buddhism in Thailand is a ‘poisoned fruit’
    America's first slavery museum established at Django Unchained plantation - 150 years after slavery outlawed

    150 years after it was outlawed...

    ... America's first slavery museum is established in Louisiana
    Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

    Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

    The first 'American Idol' winner on how she manages to remain her own woman – Jane Austen fascination and all
    Tony Oursler on exploring our uneasy relationship with technology with his new show

    You won't believe your eyes

    Tony Oursler's new show explores our uneasy relationship with technology. He's one of a growing number of artists with that preoccupation
    Ian Herbert: Peter Moores must go. He should never have been brought back to fail again

    Moores must go. He should never have been brought back to fail again

    The England coach leaves players to find solutions - which makes you wonder where he adds value, says Ian Herbert
    War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

    The battle for Mosul will unleash 'a million refugees'

    Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn